Exosome acquired for up to USD 575m

Four years ago, the btov Industrial Tech team made the investment in Exosome Diagnostics, a start-up company that presented itself to the btov group of investors as a company working on “Biofluid Diagnostics for the Next Generation of Personalized Medicine”.

This month we were surprised. Surprised by a truly great sale to NASDAQ listed Bio-Techne for up to USD 575m. I will never forget how our partner Christian Schütz explained the case to all of us again after the company presentation. Chapeau Christian and thank you with regard to our joint fund (btov II) and congratulations to all btov investors who also made the investment decision at that time. Thank you, team Exosome and wish you a truly great summer!